Rintatolimod is under clinical development by AIM ImmunoTech and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Rintatolimod’s likelihood of approval (LoA) and phase transition for Metastatic Pancreatic Cancer took place on 21 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rintatolimod Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ampligen is under development for the treatment of pancreatic cancer, HER positive breast cancer, metastatic triple negative breast cancer, colorectal cancer, HIV/AIDS infections, peritoneal cancer, melanoma, urothelial cancer, prostate cancer, long COVID complications such as COVId-19 induced myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS), post COVID -19 cognitive dysfunction (PCCD) and Ebola viral infections. The drug candidate is administered by intravenous, intraperitoneal and nasal routes. It is a synthetic derivative of inosinic acid with antiretroviral and immunomodulatory activities. Ampligen (poly I: poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching. It acts by targeting toll like receptor 3. The drug candidate is developed based on proprietary technology. It was also under development for the treatment of avian influenza (Japan, Canada), Ebola viral infections, West Nile virus infection, virus Zika infections, ovarian cancer, HIV infections H5N1, H7N9 influenza infections, renal cell carcinoma, metastatic melanoma, severe acute respiratory syndrome, non-small cell lung cancer and pandemic influenza.
AIM ImmunoTech overview
AIM ImmunoTech, formerly Hemispherx Biopharma, is an immuno- pharma company. The company focuses on the research and development of therapeutics for the treatment of multiple types of cancers, viruses and immune-deficiency disorders. Its flagship products include Ampligen (rintatolimod) sterile solution which is indicated for the treatment of patients with chronic fatigue syndrome; and Alferon N Injection used for the treatment of refractory or recurrent external condylomata acuminate. The company’s pipeline products are intended to treat various types of cancers, including ovarian, breast, colorectal, renal cell carcinoma, melanoma, pancreatic, bladder cancers, MERS and influenza virus. The company operates a production facility in New Brunswick, New Jersey. AIM ImmunoTech is headquartered in Ocala, Florida, the US.
Quick View Rintatolimod LOA Data
|Highest Development Stage|